The predictive value of the aCL and anti-β2GPI at the time of acute deep vein thrombosis—a two-year prospective study

Perdan-Pirkmajer, Katja (author), Žigon, Polona (author), Boc, Anja (author), Podovšovnik, Eva (author), Čučnik, Saša (author), Mavri, Alenka (author), Rotar, Žiga (author), Ambrožič, Aleš (author)

Antiphospholipid syndrome (APS) is an important cause of deep vein thrombosis (DVT). According to current APS classification criteria, APS cannot be confirmed until 24 weeks after DVT. This time frame results in frequent discontinuation of anticoagulant treatment before APS is diagnosed. Therefore, the aim of our study was to evaluate the potential predictive value of anticardiolipin (aCL) and anti-β2glycoprotein I (anti-β2GPI) before discontinuation of anticoagulation therapy. Patients with newly diagnosed DVT were included into a 24-month prospective study. All patients received anticoagulant therapy. aCL and anti-β2GPI were determined at inclusion and every four weeks for the first 24 weeks and then one and two years after inclusion. APS was confirmed in 24/221 (10.9%) patients. At the time of acute DVT 20/24 (83.3%), APS patients had positive aCL and/or anti-β2GPI. Two patients had low aCL levels and two were negative at the time of acute DVT but later met APS criteria due to lupus anticoagulant (LA). Our data indicate that negative aCL and/or anti-β2GPI at the time of acute DVT make further aPL testing unnecessary; however, LA should be determined after discontinuation of anticoagulant therapy. Positive aCL and/or anti-β2GPI at the time of acute DVT have a strong positive predictive value for APS and may support therapeutic decisions.

• Language: English
• Keywords: thrombosis, antiphospholipid syndrome, antiphospholipid antibodies, prediction
• Work type: Article
• Typology: 1.01 - Original Scientific Article
• Organization: MF - Faculty of Medicine; FFA - Faculty of Pharmacy
• Publication status: Published
• Publication version: Version of Record
• Year: 2021
• Number of pages: 10 str.
• Numbering: Vol. 9, iss. 8, art. 901
• PID: 20.500.12556/RUL-135957
• UDC: 616.1
• ISSN on article: 2227-9059
• DOI: 10.3390/biomedicines9080901
• COBISS.SI-ID: 72525315
• Publication date in RUL: 05.04.2022

Record is a part of a journal

• Title: Biomedicines
• Shortened title: Biomedicines
• Publisher: MDPI AG
• ISSN: 2227-9059
• COBISS.SI-ID: 523006745

Licences

• License: CC BY 4.0, Creative Commons Attribution 4.0 International
• Link: http://creativecommons.org/licenses/by/4.0/
• Description: This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
• Licensing start date: 01.08.2021

Secondary language

• Language: Slovenian
• Keywords: tromboza, antifosfolipidni sindrom, antifosfolipidna protitelesa

Projects

• Funder: ARRS - Slovenian Research Agency
• Project number: P3-0314
• Name: Sistemske avtoimunske bolezni

• Funder: ARRS - Slovenian Research Agency
• Project number: J7-8276
• Name: Vpliv protirevmatičnih zdravil na inzulinsko rezistenco in energijsko presnovo v skeletni mišici